ArticleScientific reports2026
Multimodal machine learning integrates clinical and comorbidity data to predict breast cancer prognosis and treatment outcomes.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Breast cancer prognosis and treatment outcomes are shaped by intricate interplay between tumor biology, systemic comorbidities, and patient-reported functional status. This paper introduces a framework to address critical gaps in precision oncology by systematically integrating multimodal data-including clinical parameters, comorbidity profiles, and patient-reported outcomes (PROs)-to refine prognostic stratification and therapeutic decision-making. Section 1 contextualizes the clinical relevance of comorbidity burden and quality-of-life metrics in breast cancer care, emphasizing their underutilization in conventional models. Section 2 synthesizes prior efforts in machine learning and oncology, identifying limitations in single-modality approaches and underscoring the necessity for holistic data integration. Section 3 describes the harmonization of structured clinical variables, binary comorbidity flags, and EORTC QLQ-C30/BR23 scores from a prospective cohort of 1727 patients, alongside methodological innovations for handling missingness and feature engineering. Section 4 outlines experimental protocols for model training, cross-validation, and ablation studies to quantify the incremental value of multimodal inputs. Section 5 highlights key insights into prognostic heterogeneity, including the differential impacts of specific comorbidities (e.g., urinary tract infections, depression) and PRO domains (e.g., fatigue, global health status) on survival trajectories. Section 6 interprets these findings through the lens of clinical utility, addressing scalability challenges and ethical considerations for real-world deployment. Finally, Sect. 7 proposes translational pathways for embedding multimodal analytics into risk-adapted treatment paradigms. This work bridges computational innovation with patient-centered care, offering a roadmap for advancing precision oncology through data-driven, multidimensional modeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.